[1] Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report:primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014[J]. Neuro Oncol, 2017, 19:V1-88.
[2] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65:87-108.
[3] Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma:a randomized clinical trial[J]. JAMA, 2017, 318:2306-2316.
[4] U.S. Food and Drug Administration 2011 NovoTTF-100A System-Premarket Approval P100034[DB/OL]. 2011[2019-10-01]. https://www.accessdata.fda.gov/cdrh_docs/pdf10/p100034a.pdf.
[5] U.S. Food and Drug Administration 2015 OPTUNE (Formerly the NovoTTF-100A System)-Expanded Indication Approval P100034S013[DB/OL]. 2015[2019-10-01]. https://www.accessdata.fda.gov/cdrh_docs/pdf10/P100034S013b.pdf.
[6] NCCN clinical practice guidelines in oncology:central nervous system cancers (2018.V1)[DB/OL]. 2018[2019-10-01]. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
[7] National Health Commission Medical Administration. Diagnosis and treatment of brain glioma (2018)[J]. Zhonghua Shen Jing Wai Ke Za Zhi, 2019, 35:217-239.[国家卫生健康委员会医政医管局. 脑胶质瘤诊疗规范(2018年版)[J]. 中华神经外科杂志, 2019, 35:217-239.]
[8] Zimmermann U, Vienken J, Pilwat G. Rotation of cells in an alternating electric field:the occurrence of a resonance frequency[J]. Z Naturforsch C Biosci, 1981, 36:173-177.
[9] Holzapfel C, Vienken J, Zimmermann U. Rotation of cells in an alternating electric field:theory and experimental proof[J]. J Membr Biol, 1982, 67:13-26.
[10] Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y. Disruption of cancer cell replication by alternating electric fields[J]. Cancer Res, 2004, 64:3288-3295.
[11] Kirson ED, Dbalý V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors[J]. Proc Natl Acad Sci USA, 2007, 104:10152-10157.
[12] Gera N, Yang A, Holtzman TS, Lee SX, Wong ET, Swanson KD. Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit[J]. PLoS One, 2015, 10:E0125269.
[13] Giladi M, Schneiderman RS, Voloshin T, Porat Y, Munster M, Blat R, Sherbo S, Bomzon Z, Urman N, Itzhaki A, Cahal S, Shteingauz A, Chaudhry A, Kirson ED, Weinberg U, Palti Y.Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells[J]. Sci Rep, 2015, 5:18046.
[14] Karanam NK, Srinivasan K, Ding L, Sishc B, Saha D, Story MD. Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines[J]. Cell Death Dis, 2017, 8:E2711.
[15] Kirson ED, Giladi M, Gurvich Z, Itzhaki A, Mordechovich D, Schneiderman RS, Wasserman Y, Ryffel B, Goldsher D, Palti Y. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs[J]. Clin Exp Metastasis, 2009, 26:633-640.
[16] Kim EH, Song HS, Yoo SH, Yoon M. Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis[J]. Oncotarget, 2016, 7:65125-65136.
[17] Pavesi A, Adriani G, Tay A, Warkiani ME, Yeap WH, Wong SC, Kamm RD. Engineering a 3D microfluidic culture platform for tumor-treating field application[J]. Sci Rep, 2016, 6:26584.
[18] Kirson ED, Schneiderman RS, Dbalý V, Tovarys F, Vymazal J, Itzhaki A, Mordechovich D, Gurvich Z, Shmueli E, Goldsher D, Wasserman Y, Palti Y. Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields)[J]. BMC Med Phys, 2009, 9:1.
[19] Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbalý V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma:a randomised phase Ⅲ trial of a novel treatment modality[J]. Eur J Cancer, 2012, 48:2192-2202.
[20] Wenger C, Miranda PC, Salvador R, Thielscher A, Bomzon Z, Giladi M, Mrugala MM, Korshoej AR. A review on tumor -treating fields (TTFields):clinical implications inferred from computational modeling[J]. IEEE Rev Biomed Eng, 2018, 11:195-207.
[21] Korshoej AR, Saturnino GB, Rasmussen LK, von Oettingen G, Sørensen JC, Thielscher A. Enhancing predicted efficacy of tumor treating fields therapy of glioblastoma using targeted surgical craniectomy:a computer modeling study[J]. PLoS One, 2016, 11:E0164051.
[22] Salzberg M, Kirson E, Palti Y, Rochlitz C. A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors[J]. Onkologie, 2008, 31:362-365.
[23] Ram Z, Gutin P. NO-55. Subgroup and quality of life analyses of the phase Ⅲ clinical trial of NovoTTF-100A versus best standard chemotherapy for recurrent glioblastoma[J]. Neuro Oncol, 2010, 12(suppl_4):iv48.
[24] Toms SA, Kim CY, Nicholas G, Ram Z. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma:a subgroup analysis of the EF-14 phase Ⅲ trial[J]. J Neurooncol, 2019, 141:467-473.
[25] Butowski N, Wong ET, Mehta MP, Wilson LK. A roundtable discussion on the clinical challengesand options for the treatment of glioblastoma:introducing a novel modality, TTFields[J]. Semin Oncol, 2013, 40:S2-4.
[26] Editing Group of "Guidelines for diagnosis and treatment of central nervous system gliomas in China". Guidelines for diagnosis and treatment of central nervous system gliomas in China (2015)[J]. Zhonghua Yi Xue Za Zhi, 2016, 96:485-509.[《中国中枢神经系统胶质瘤诊断和治疗指南》编写组. 中国中枢神经系统胶质瘤诊断与治疗指南(2015)[J]. 中华医学杂志, 2016, 96:485-509.]
[27] Jeyapalan SA, Toms SA, Hottinger AF, Kleinberg L, Pollom E, Soltys SG, Glas M. Analysis of the EF-14 phase Ⅲ trial reveals that tumor treating fields alter progression patterns in glioblastoma[J]. J Clin Oncol, 2019, 37(15_suppl):2055.
[28] Liu Y, Richardson M, Warren K, Strawderman MS, Mohile N, Milano MT, Walter K. Clinical efficacy of tumor-treating fields for newly diagnosed glioblastoma[J]. J Clin Oncol, 2019, 37(15_suppl):2046.